See more : MHM Automation Limited (MHM.NZ) Income Statement Analysis – Financial Results
Complete financial analysis of AzurRx BioPharma, Inc. (AZRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AzurRx BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- HYUGA PRIMARY CARE Co.,Ltd. (7133.T) Income Statement Analysis – Financial Results
- Linc Limited (LINCPEN.NS) Income Statement Analysis – Financial Results
- Radaan Mediaworks India Limited (RADAAN.BO) Income Statement Analysis – Financial Results
- Ashanti Sankofa Inc. (AMIQF) Income Statement Analysis – Financial Results
- Basler Kantonalbank (0QLU.L) Income Statement Analysis – Financial Results
AzurRx BioPharma, Inc. (AZRX)
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5,888.00B | 8.68M | 4.99M | 2.40M | 2.50M | 1.40M |
| General & Administrative | 7.29M | 6.06M | 8.24M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.29M | 6.06M | 8.24M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 20,544.76B | 0.00 | 210.00K | 7.69M | 4.13M | -4.73M |
| Operating Expenses | 26,432.77B | 14.74M | 13.43M | 10.08M | 6.63M | -3.33M |
| Cost & Expenses | 26,432.77B | 14.74M | 13.43M | 10.08M | 6.63M | 4.73M |
| Interest Income | 484.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5,840.61B | 433.94K | 101.85K | 875.20K | 5.94M | 1.59M |
| Depreciation & Amortization | 37.80K | 1.02M | 798.45K | 754.00K | 734.50K | 733.60K |
| EBITDA | -26,830.85B | -13.72M | -12.63M | -9.47M | -7.92M | -3.61M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -26,432.77B | -14.74M | -13.43M | -10.08M | -6.63M | -4.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6,238.70B | -433.94K | -101.85K | -1.02M | -7.97M | -1.20M |
| Income Before Tax | -32,671.47B | -15.18M | -13.53M | -11.10M | -14.59M | -5.93M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -398.08B | 0.00 | 0.00 | -140.00K | -2.03M | 386.11K |
| Net Income | -32,671.47B | -15.18M | -13.53M | -11.10M | -14.59M | -5.93M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.90M | -6.77 | -8.77 | -10.44 | -22.43 | -6.16 |
| EPS Diluted | -5.90M | -6.77 | -8.77 | -10.44 | -22.43 | -6.16 |
| Weighted Avg Shares Out | 5.53M | 2.24M | 1.54M | 1.06M | 650.48K | 963.11K |
| Weighted Avg Shares Out (Dil) | 5.53M | 2.24M | 1.54M | 1.06M | 650.48K | 963.11K |
New Strong Sell Stocks for August 5th
AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter's Option to Purchase Additional Shares
Biotech Penny Stocks Are Heating Up, Here's 3 To Watch Right Now
AZRX Stock Increases Over 19% Pre-Market: Why It Happened
AzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 Million
AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock
AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital
AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)
AzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit)
AzurRx BioPharma to Present at the Emerging Growth Conference (May 12)
Source: https://incomestatements.info
Category: Stock Reports